Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Bausch Health

Status and phase: Completed; Phase 2

Conditions: Psoriasis

Treatments: Drug: IDP-118 Vehicle Lotion; Drug: IDP-118 Lotion; Drug: IDP-118 Vehicle Cream; Drug: Tazorac Cream

Study type: Interventional

Funder types: Industry

Identifiers

NCT02785159

V01-118A-202

Details and patient eligibility

About

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Full description

A Phase 2, Multicenter, Double-Blinded, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion with Tazorac (tazarotene) Cream, 0.05% in the Treatment of Plaque Psoriasis

Enrollment: 152 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Male or female, of any race, at least 18 years of age (inclusive).
• Freely provides both verbal and written informed consent.
• Has an area of plaque psoriasis appropriate for topical treatment that covers a Body Surface Area (BSA) of at least 3%, but no more than 12%. The face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded in this calculation.
• Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study.
• Has a clinical diagnosis of psoriasis at the Baseline visit with an (IGA) Investigator Global Assessment score of 3 or 4. (The face, scalp, palms, soles, axillae and intertriginous areas are to be excluded in this assessment, if psoriasis is present.)

Key Exclusion Criteria:

• Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined by the investigator.
• Presents with psoriasis that was treated with prescription medication and failed to respond to treatment, even partially or temporarily, as determined by the investigator.
• Presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the investigator.
• Is pregnant, nursing an infant, or planning a pregnancy during the study period.
• Has received treatment with any investigational drug or device within 60 days or 5 drug half-lives (whichever is longer) prior to the Baseline visit, or is concurrently participating in another clinical study with an investigational drug or device.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

152 participants in 4 patient groups

IDP-118 Lotion

Experimental group

Description:

Lotion

Treatment:

Drug: IDP-118 Lotion

Tazorac Cream

Active Comparator group

Description:

Cream

Treatment:

Drug: Tazorac Cream

IDP 118 Vehicle Lotion

Active Comparator group

Description:

Lotion

Treatment:

Drug: IDP-118 Vehicle Lotion

IDP-118 Vehicle Cream

Active Comparator group

Description:

Cream

Treatment:

Drug: IDP-118 Vehicle Cream